



# LA AI 2026

## 2<sup>ND</sup> INTERNATIONAL WORKSHOP ON LONG-ACTING ANTI-INFECTIVES

HYBRID WORKSHOP | 20-21 MAY 2026 | PHILADELPHIA, UNITED STATES

09/04/2026

### DAY 1: Wednesday, May 20

|   |          |  |   |
|---|----------|--|---|
| 00:30   | 8:30 AM  | <b>Welcome Coffee</b>  |   |
| 00:10   | 9:00 AM  | <b>Official Opening</b>  |   |
| <b>Session 1: Long-Acting Platforms</b>                                       |          |  |   |
| 00:20   | 9:10 AM  | <b>Innovative Modalities for Delivering Long-Acting Antivirals</b>   | <b>Andrew Owen,</b><br>University of Liverpool, United Kingdom  |
| 00:15   | 9:30 AM  | <b>Gilead - HSV Long Acting Compounds</b>  | <b>Alexandre Mercier,</b><br>Gilead Sciences, Inc., United States   |
| 00:15   | 9:45 AM  | <b>Advancing long-acting injectables with BEPO® in situ forming depot technology</b>   | <b>Sylvestre Grizot,</b><br>MedinCell, France   |
| 00:15   | 10:00 AM | <b>DART</b>  | <b>Alessandro Gattoni,</b><br>Center for BioNanoengineering, Houston Methodist Hospital,<br>Houston, Texas, USA |
| 00:20   | 10:15 AM | Q & A /Discussion  |   |
| 00:30   | 10:35 AM | <b>Coffee Break</b>  |   |
| <b>Session 2: Long-Acting Approaches for Prevention</b>                       |          |  |   |
| 00:20   | 11:05 AM | <b>User Preferences and Considerations in Designing Prevention Strategies</b>  | <b>José A. Bauermeister,</b><br>University of Pennsylvania, United States                                       |
| 00:20   | 11:25 AM | <b>Treatment of HBV as Prevention of Liver Cancer</b>  | <b>Chari A. Cohen,</b><br>Hepatitis B Foundation, Baruch S. Blumberg Institute, United States                   |
| 00:10   | 11:45 AM | <b>#1 PrEP-naïve Lenacapavir Initiators More Likely to be Assigned Female Sex at Birth in a Real-World Cohort</b>  | <b>Meredith Edwards Clement,</b><br>Beth Israel Deaconess Medical Center, United States                         |
| 00:10   | 11:55 AM | <b>#2 The Use of PBPK Modelling to Assess the Need for Simultaneous Oral Initiation with Long-Acting Cabotegravir and Rilpivirine in the Setting of Post-exposure Prophylaxis (PEP).</b> | <b>Doaa Ahmed Mohamed,</b><br>University of Liverpool, United Kingdom   |
| 00:10   | 12:05 PM | <b>#3 Adherence to Oral versus Long-acting Injectable HIV Preexposure Prophylaxis among Women who Inject Drugs</b>   | <b>Douglas Krakower,</b><br>Beth Israel Deaconess Medical Center, United States                                 |
| 00:10   | 12:15 PM | <b>#4 Early Patient-Reported Outcomes and Planned Persistence With Lenacapavir for HIV Pre-Exposure Prophylaxis in Routine Clinical Care</b>   | <b>Aniruddha Hazra,</b><br>University of Chicago, United States   |
| 00:20   | 12:25 PM | Q & A /Discussion  |   |
| 01:00   | 12:45 PM | <b>Lunch</b>   |   |
| <b>Session 3: Long-Acting Therapeutics Beyond HIV</b>                         |          |  |   |
| 00:20   | 1:45 PM  | <b>Update on the Use of Long-acting Monoclonal Antibodies for Malaria Prevention</b>   | <b>Kirsten E. Lyke,</b><br>Center for Vaccine Development and Global Health, United States                      |
| 00:20   | 2:05 PM  | <b>Long-Acting for Hepatitis C: Treatment and Cure</b>   | <b>David Thomas,</b><br>Johns Hopkins School of Medicine, Baltimore, United States                              |
| 00:10   | 2:25 PM  | <b>#5 Long-Acting Injectable Treatment for Tuberculosis: Multi-Country Cross-Sectional Study to Examine Preferences, Acceptability, and Trade-Offs</b>                                   | <b>Christopher Vinnard,</b><br>Gates MRI, United States   |
| 00:10   | 2:35 PM  | <b>#6 A Regulatory Strategy for Long-Acting Injectable Regimens for Tuberculosis</b>   | <b>Liz Daglish,</b><br>Gates MRI, United States   |
| 00:15   | 2:45 PM  | Q & A /Discussion  |   |
| 00:30   | 3:00 PM  | <b>Coffee Break &amp; Poster Viewing</b>   |   |
| <b>Session 4: Therapeutic Considerations using LA-ARVS in Key Populations</b> |          |  |   |



|                                  |         |   |   |
|----------------------------------|---------|---|---|
| 00:20                            | 3:30 PM | <b>Behavioral Considerations and Adherence Strategies for People Who Use Drugs</b>  | <b>Sunil Solomon,</b><br>Johns Hopkins University, United States                                |
| 00:20                            | 3:50 PM | <b>Use of CAB/RPV during Pregnancy</b>  | <b>William Short,</b><br>University of Pennsylvania, United States                              |
| 00:10                            | 4:10 PM | #7 Clinician Attitudes Toward and Utilization of Long-Acting Injectable Cabotegravir/Rilpivirine for Pregnant Persons Living With HIV                                   | <b>Owen M. Parra,</b><br>University of Pennsylvania, Perelman School of Medicine, United States |
| 00:10                            | 4:20 PM | #8 PREFER-LA: Improved Adherence and Viral Control in Real-World Study of People With HIV in the United States With Adherence Challenges on Oral Antiretroviral Therapy | <b>Paula Teichner,</b><br>ViiV HealthCare, United States  |
| 00:10                            | 4:30 PM | #9 Rethinking Eligibility: Long-Acting Cabotegravir/Rilpivirine Achieves Suppression in Viremic Individuals: From the Midway Cohort                                     | <b>Hector Bolivar,</b><br>Midway Specialty Care Center, United States                           |
| 00:20                            | 4:40 PM | Q & A /Discussion   |   |
| 5:00 PM <b>End of Day 1</b>      |         |   |   |
| 7:00 PM <b>Networking Dinner</b> |         |   |   |

## DAY 2: Thursday, May 21

### Session 5: Long-Acting Antiretrovirals - Resistance

|   |          |   |   |
|---|----------|---|---|
| 00:20   | 9:00 AM  | <b>Development of Resistance to bNABs</b>   | <b>Katharine Bar,</b><br>Perelman School of Medicine, University of Pennsylvania, United States             |
| 00:20   | 9:20 AM  | <b>Resistance Globally and Its Impact on the Use of Long-acting Antiretrovirals</b>   | <b>Michael Jordan,</b><br>Tufts University and Tufts Medical Center, Boston, MA, USA                        |
| 00:10   | 9:40 AM  | #10 How Long-Acting Anti-Infective mAbs Can Catalyze Global mAb Pharmacoequity  | <b>Huub Gelderblom,</b><br>HVTN (HIV Vaccine Trials Network) / Fred Hutchinson Cancer Center, United States |
| 00:10   | 9:50 AM  | #11 Maintenance of HIV-1 Suppression at 12 Months With Lotivibart (LVB; VH3810109, N6LS) Every 4 Months + CAB LA Every Month: The EMBRACE Study   | <b>Margaret Gartland,</b><br>ViiV HealthCare, United States   |
| 00:10   | 10:00 AM | #12 ACC085, a novel HIV-1 capsid function inhibitor, exhibits human pharmacokinetics predicted from nonclinical data using a PBPK model, supporting its long-acting potential in humans | <b>Qin Hong,</b><br>Jiangsuaidapharmaceutical, China  |
| 00:20   | 10:10 AM | Q & A /Discussion   |   |
| 10:30 AM <b>Coffee Break &amp; Poster Viewing</b> |          |   |   |

### Session 6: Managing Low-Level Viremia – What Is the Best Approach?

|                      |          |  |   |
|----------------------|----------|--|---|
| Chair: Dan Kuritzkes |          |  |   |
| 00:20                | 11:00 AM | <b>Management of low-level viremia among people who have already been started on long-acting ART</b>   | <b>Ethel Weld,</b><br>Johns Hopkins University School of Medicine, Baltimore, United States |
| 00:10                | 11:20 AM | #13 Leveraging Pharmacists and Pharmacy Technicians to Optimize Long-Acting Injectable Antiretroviral Therapy Access, Adherence, and Clinical Outcomes | <b>Katerina A. Christopoulos,</b><br>University of California San Francisco, United States  |
| 00:10                | 11:30 AM | #14 On-time injection adherence and persistence among people with HIV on long-acting cabotegravir/rilpivirine  | <b>Yotam Arens,</b><br>Weill Cornell Medicine, United States                                |
| 00:20                | 11:40 AM | <b>Discussion on Low level Viremia</b>   | <Onsite Faculty>  |

**12:00 PM Industry - Supported session**

1:00 PM **Lunch**

### Session 7: Long-Acting Anti-Infectives: What will the future hold?

|       |         |   |  |
|-------|---------|---|--|
| 00:20 | 2:00 PM | <b>Invited Lecture</b>  | <b>Pablo Tebas,</b><br>University of Pennsylvania, United States |
| 00:10 | 2:20 PM | #15 In-Country Evaluation of Compact Prefilled Autodisable Devices for Delivery of Long-Acting Medicines in Uganda and Zambia | <b>Courtney Jarrahian,</b><br>PATH, United States                |
| 00:10 | 2:30 PM | #16 A Novel Islatravir Prodrug Formulated as a Long-Acting Nanosuspension for HIV Treatment                                   | <b>Sijia Tao,</b><br>Emory University, United States             |



00:10 2:40 PM #17 Pharmacokinetics and Evaluation of Potential Dosing Regimens for Long-Acting VH4524184

*Hyunmoon Back,  
GSK, United States*

00:10 2:50 PM #18 Injectable HIV-1 Capsid Inhibitor VH4011499 (VH-499) Formulation Supports Twice-Yearly Dosing

*Jose R. Castillo-Mancilla,  
ViiV HealthCare, United States*

00:10 3:00 PM Q & A /Discussion

00:05 3:10 PM Closing Remarks

**3:15 PM** *End of the Program*